ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5330ometendo-5330Research ArticleСтатьиArticlesЭффективность применения препарата Роглит у больных сахарным диабетом 2 типаEffektivnost' primeneniya preparata Roglit u bol'nykh sakharnym diabetom 2 tipaRomantsovaT I-VolkovaG E-RoikO V-PoluboyarinovaI V-20081509200853№3 (2008)712Copyright © Romantsova T.I., Volkova G.E., Roik O.V., Poluboyarinova I.V., 20082008Romantsova T.I., Volkova G.E., Roik O.V., Poluboyarinova I.V.Romantsova T.I., Volkova G.E., Roik O.V., Poluboyarinova I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5330ReferencesCefalu W.T. Insulin resistance: cellular and clinical concepts.// Experimental Biology and Medicine. - 2001; 226: 13-26.Cefalu W.T. Insulin resistance: cellular and clinical concepts.// Experimental Biology and Medicine. - 2001; 226: 13-26.Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files.// Sciense.- 2001; 294 (5548): 1866-1870.Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files.// Sciense.- 2001; 294 (5548): 1866-1870.Cheng A.Y.Y., Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mel-litus. //Can. Med. Assoc. J. - 2005;172(2): 213-226.Cheng A.Y.Y., Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mel-litus. //Can. Med. Assoc. J. - 2005;172(2): 213-226.Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. //Endocr. Rev. -1999; 20: 649-688.Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. //Endocr. Rev. -1999; 20: 649-688.Ferre` P. The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and insulin sensitivity.// Diabetes. - 2004; 53: 43-50.Ferre` P. The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and insulin sensitivity.// Diabetes. - 2004; 53: 43-50.H. Yki-Jarvinen. Thiazolidinediones. // N. Engl. J. Med. - 2004; 351(11): 1106-1118.H. Yki-Jarvinen. Thiazolidinediones. // N. Engl. J. Med. - 2004; 351(11): 1106-1118.Jiang, C., Ting, A.T. & Seed, B. PPAR- agonists inhibit production of monocyte inflammatory cytokines.// Nature. - 2001; 391: 82-86.Jiang, C., Ting, A.T. & Seed, B. PPAR- agonists inhibit production of monocyte inflammatory cytokines.// Nature. - 2001; 391: 82-86.Kintscher U., Law R.E. PPAR{gamma}-mediated insulin sensitization: the importance of fat versus muscle.//Am. J. Physiol. Endocrinol. Metab. - 2005; 288(2): 287-291.Kintscher U., Law R.E. PPAR{gamma}-mediated insulin sensitization: the importance of fat versus muscle.//Am. J. Physiol. Endocrinol. Metab. - 2005; 288(2): 287-291.Lebovitz H.E., Dole J.F., Patwardhan R. et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. //J. Clin. Endocrinol. Metab. - 2001; 86: 280-288.Lebovitz H.E., Dole J.F., Patwardhan R. et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. //J. Clin. Endocrinol. Metab. - 2001; 86: 280-288.Lee C., Olson P., Ronald M. Evans R. M. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.// Endocrinology. - 2003; 144 (6): 2201-2207.Lee C., Olson P., Ronald M. Evans R. M. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.// Endocrinology. - 2003; 144 (6): 2201-2207.Madan P. Effect of thiazolidinediones on lipid profile. //Can. Med. Assoc. J., August 16, 2005; 173(4): 344-344.Madan P. Effect of thiazolidinediones on lipid profile. //Can. Med. Assoc. J., August 16, 2005; 173(4): 344-344.Maeda N., Takahashi M., Funahashi T. et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived pro-tein.// Diabetes.- 2001; 50: 2094-2099.Maeda N., Takahashi M., Funahashi T. et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived pro-tein.// Diabetes.- 2001; 50: 2094-2099.Nissen S.E, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. // N. Engl. J. Med. - 2007; 356(24): 2457-2471.Nissen S.E, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. // N. Engl. J. Med. - 2007; 356(24): 2457-2471.Rosen E.D., Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth.// J. Biol. Chem. - 2001; 276: 37731-37734.Rosen E.D., Spiegelman B.M. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth.// J. Biol. Chem. - 2001; 276: 37731-37734.Schiffrin E. L., Amiri F., Benkirane K. Et al. Peroxisome proliferator-activated receptors. Vascular and cardiac effects in hypertension. //Hypertension. - 2003; 42: 664-672.Schiffrin E. L., Amiri F., Benkirane K. Et al. Peroxisome proliferator-activated receptors. Vascular and cardiac effects in hypertension. //Hypertension. - 2003; 42: 664-672.Shao D., Lazar M. A. Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation.// J. Biol. Chem. -1997; 272: 21473-21478.Shao D., Lazar M. A. Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation.// J. Biol. Chem. -1997; 272: 21473-21478.van Wijk J. P.H., de Koning E. J.P; Martens E. P.; Rabelink J.T. Thiazolidinediones and blood lipids in type 2 diabetes. //Arteriosclerosis, Thrombosis, and Vascular Biology. - 2003; 23:1744-1750.van Wijk J. P.H., de Koning E. J.P; Martens E. P.; Rabelink J.T. Thiazolidinediones and blood lipids in type 2 diabetes. //Arteriosclerosis, Thrombosis, and Vascular Biology. - 2003; 23:1744-1750.Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism.// J. Lipid. Res. - 2002; 43: 177-186.Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism.// J. Lipid. Res. - 2002; 43: 177-186.Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. //Annu. Rev. Biochem. - 2001; 70: 341-367.Willson T.M., Lambert M.H., Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. //Annu. Rev. Biochem. - 2001; 70: 341-367.Yu J.G., Javorschi S., Hevener A.L. et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. //Diabetes. - 2002; 5: 2968-2974.Yu J.G., Javorschi S., Hevener A.L. et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. //Diabetes. - 2002; 5: 2968-2974.
The authors declare that there are no conflicts of interest present.